• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿尔茨海默病治疗的新视角:脂质体利斯的明制剂。

New perspective for the treatment of Alzheimer diseases: liposomal rivastigmine formulations.

机构信息

Department of Pharmaceutical Technology, Gazi University Faculty of Pharmacy, Ankara.

出版信息

Drug Dev Ind Pharm. 2011 Jul;37(7):775-89. doi: 10.3109/03639045.2010.541262. Epub 2011 Jan 14.

DOI:10.3109/03639045.2010.541262
PMID:21231901
Abstract

The aim of this study was to determine the transportations of rivastigmine containing from various liposome formulations through Madin Darby Canine Kidney (MDCK) cells monolayer and to compare the in vitro test results with in vivo. There is no other liposome formulation of rivastigmine and the transportations of rivastigmine through MDCK cell monolayers or related study available in the literature. Cytotoxicity (MTT) test was used to determine cell viabilities. The effect of sodium-taurocholate or dimethyl-beta-cyclodextrine as penetration enhancer was also investigated. Characterization and stability studies for liposome formulations were performed. Permeation experiments of rivastigmine were performed through MDCK cells and dialysis membrane. The kinetic of release from liposomes was also investigated. The highest apparent permeability coefficient (log. values) was obtained with sodium-taurocholate liposomes for -1.15 ± 0.16 for MDCK cell. Rivastigmine liposomes and solutions were also administered to mice orally and intraperitonally. Acetylcholinesterase (AChE) activity was determined by Ellman method. AChE% inhibition values were calculated for both blood and brain after administration of rivastigmine solution and liposomes. The highest AChE inhibition was observed for rivastigmine-sodium-taurocholate liposomes. Histological observations of the mice' brains were performed under transmission electron microscope (TEM). The histological results were also indicated and supported all these findings.

摘要

本研究旨在确定不同脂质体配方中含有利伐斯的明的转运情况,通过 Madin Darby 犬肾 (MDCK) 细胞单层,并将体外试验结果与体内进行比较。目前尚无其他利伐斯的明脂质体配方,也没有文献报道利伐斯的明通过 MDCK 细胞单层的转运或相关研究。细胞毒性 (MTT) 试验用于测定细胞活力。还研究了牛磺胆酸钠或二甲基-β-环糊精作为渗透增强剂的作用。对脂质体配方进行了特性和稳定性研究。通过 MDCK 细胞和透析膜进行了利伐斯的明渗透实验。还研究了从脂质体中释放的动力学。对于 MDCK 细胞,牛磺胆酸钠脂质体的表观渗透系数 (log 值) 最高,为 -1.15 ± 0.16。还通过口服和腹腔内给药将利伐斯的明脂质体和溶液施用于小鼠。乙酰胆碱酯酶 (AChE) 活性通过 Ellman 法测定。给药后,计算了血液和大脑中的 AChE%抑制值利伐斯的明溶液和脂质体。牛磺胆酸钠脂质体观察到最高的 AChE 抑制。在透射电子显微镜 (TEM) 下对小鼠大脑进行了组织学观察。组织学结果也表明并支持了所有这些发现。

相似文献

1
New perspective for the treatment of Alzheimer diseases: liposomal rivastigmine formulations.阿尔茨海默病治疗的新视角:脂质体利斯的明制剂。
Drug Dev Ind Pharm. 2011 Jul;37(7):775-89. doi: 10.3109/03639045.2010.541262. Epub 2011 Jan 14.
2
Investigation of liposome formulation effects on rivastigmine transport through human colonic adenocarcinoma cell line (CACO-2).脂质体制剂对卡巴拉汀透过人结肠腺癌细胞系(CACO-2)转运影响的研究。
Pharmazie. 2010 Jan;65(1):32-40.
3
Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration.经鼻腔给予脂质体后,利斯的明的脑分布和药效增强。
Int J Pharm. 2013 Aug 16;452(1-2):344-54. doi: 10.1016/j.ijpharm.2013.05.009. Epub 2013 May 13.
4
[Preparation of rivastigmine liposome and its pharmacokinetics in rats after intranasal administration].[卡巴拉汀脂质体的制备及其鼻腔给药后在大鼠体内的药代动力学]
Yao Xue Xue Bao. 2011 Jul;46(7):859-63.
5
The effect of various liposome formulations on insulin penetration across Caco-2 cell monolayer.各种脂质体制剂对胰岛素透过Caco-2细胞单层的影响。
Life Sci. 2004 Oct 22;75(23):2819-27. doi: 10.1016/j.lfs.2004.05.027.
6
A study of rivastigmine liposomes for delivery into the brain through intranasal route.一项关于通过鼻内途径将卡巴拉汀脂质体递送至大脑的研究。
Acta Pharm. 2008 Sep;58(3):287-97. doi: 10.2478/v10007-008-0014-3.
7
Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain.美金刚与卡巴拉汀联合用药对大鼠脑内体外或离体测定的乙酰胆碱酯酶抑制作用没有影响。
Neuropharmacology. 2004 Sep;47(3):408-13. doi: 10.1016/j.neuropharm.2004.04.009.
8
Pharmacokinetic rationale for the rivastigmine patch.卡巴拉汀贴片的药代动力学原理。
Neurology. 2007 Jul 24;69(4 Suppl 1):S10-3. doi: 10.1212/01.wnl.0000281846.40390.50.
9
Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting.载瑞伐他汀壳聚糖纳米粒的制备及脑靶向评价。
Eur J Pharm Sci. 2012 Aug 30;47(1):6-15. doi: 10.1016/j.ejps.2012.04.013. Epub 2012 Apr 27.
10
Bioequivalence evaluation of two brands of rivastigmine of different salt forms, an acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, in healthy Beagle dogs.
Pharmazie. 2011 Aug;66(8):590-3.

引用本文的文献

1
Single and Multitarget Systems for Drug Delivery and Detection: Up-to-Date Strategies for Brain Disorders.用于药物递送和检测的单靶点和多靶点系统:脑部疾病的最新策略
Pharmaceuticals (Basel). 2023 Dec 12;16(12):1721. doi: 10.3390/ph16121721.
2
Multifunctional Nanocarriers for Alzheimer's Disease: Befriending the Barriers.多功能纳米载体治疗阿尔茨海默病:突破障碍。
Mol Neurobiol. 2024 May;61(5):3042-3089. doi: 10.1007/s12035-023-03730-z. Epub 2023 Nov 15.
3
Advances and Opportunities in Nanoparticle Drug Delivery for Central Nervous System Disorders: A Review of Current Advances.
用于中枢神经系统疾病的纳米颗粒药物递送的进展与机遇:当前进展综述
Cureus. 2023 Aug 29;15(8):e44302. doi: 10.7759/cureus.44302. eCollection 2023 Aug.
4
Nanotechnology-empowered therapeutics targeting neurodegenerative diseases.纳米技术赋能的神经退行性疾病治疗策略。
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2023 Sep-Oct;15(5):e1907. doi: 10.1002/wnan.1907. Epub 2023 May 30.
5
Exosome-based approaches in the management of Alzheimer's disease.基于外泌体的阿尔茨海默病治疗方法。
Neurosci Biobehav Rev. 2023 Jan;144:104974. doi: 10.1016/j.neubiorev.2022.104974. Epub 2022 Nov 23.
6
A Comparative Study of Quercetin-Loaded Nanocochleates and Liposomes: Formulation, Characterization, Assessment of Degradation and In Vitro Anticancer Potential.载槲皮素纳米耳蜗状脂质体与脂质体的比较研究:制剂、表征、降解评估及体外抗癌潜力
Pharmaceutics. 2022 Jul 31;14(8):1601. doi: 10.3390/pharmaceutics14081601.
7
Lipid-Based Nanocarriers for Neurological Disorders: A Review of the State-of-the-Art and Therapeutic Success to Date.用于神经疾病的脂质基纳米载体:最新技术水平及迄今治疗成功情况综述
Pharmaceutics. 2022 Apr 11;14(4):836. doi: 10.3390/pharmaceutics14040836.
8
Nanotherapeutics for Nose-to-Brain Drug Delivery: An Approach to Bypass the Blood Brain Barrier.用于鼻-脑给药的纳米疗法:一种绕过血脑屏障的方法
Pharmaceutics. 2021 Nov 30;13(12):2049. doi: 10.3390/pharmaceutics13122049.
9
Liposome based drug delivery as a potential treatment option for Alzheimer's disease.基于脂质体的药物递送作为阿尔茨海默病的一种潜在治疗选择。
Neural Regen Res. 2022 Jun;17(6):1190-1198. doi: 10.4103/1673-5374.327328.
10
Physiological and Pathological Factors Affecting Drug Delivery to the Brain by Nanoparticles.影响纳米颗粒向大脑递药的生理和病理因素。
Adv Sci (Weinh). 2021 Jun;8(11):e2002085. doi: 10.1002/advs.202002085. Epub 2021 Mar 15.